Transcriptional Repressor Blimp-1 Promotes CD8+ T Cell Terminal Differentiation and Represses the Acquisition of Central Memory T Cell Properties  by Rutishauser, Rachel L. et al.
Immunity
ArticleTranscriptional Repressor Blimp-1 Promotes CD8+
T Cell Terminal Differentiation and Represses the
Acquisition of Central Memory T Cell Properties
Rachel L. Rutishauser,1 Gislaˆine A. Martins,3,5 Sergey Kalachikov,2 Anmol Chandele,1 Ian A. Parish,1 Eric Meffre,1
Joshy Jacob,4 Kathryn Calame,3 and Susan M. Kaech1,*
1Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520, USA
2Columbia Genome Center
3Department of Biochemistry and Molecular Biophysics
Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
4Department of Microbiology and Immunology, Emory Vaccine Center, Yerkes National Primate Center,
Emory University School of Medicine, Atlanta, GA 30322, USA
5Present address: Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
*Correspondence: susan.kaech@yale.edu
DOI 10.1016/j.immuni.2009.05.014SUMMARY
During acute infections, a small population of effector
CD8+ T cells evades terminal differentiation and
survives as long-lived memory T cells. We demon-
strate that the transcriptional repressor Blimp-1
enhanced the formation of terminally differentiated
CD8+ T cells during lymphocytic choriomeningitis
virus (LCMV) infection, and Blimp-1 deficiency
promoted the acquisition of memory cell properties
by effector cells. Blimp-1 expression was preferen-
tially increased in terminally differentiated effector
and ‘‘effector memory’’ (Tem) CD8+ T cells, and grad-
ually decayed after infection as central memory (Tcm)
cells developed. Blimp-1-deficient effector CD8+
T cells showed some reduction in effector molecule
expression, but primarily developed into memory
precursor cells that survived better and more rapidly
acquired several Tcm cell attributes, including CD62L
and IL-2 expression and enhanced proliferative
responses. These results reveal a critical role for
Blimp-1 in controlling terminal differentiation and
suppressing memory cell developmental potential in
effector CD8+ T cells during viral infection.
INTRODUCTION
Memory T cells are a major component of long-term immunity
because of their longevity and other unique properties that
include the ability to maintain a high proliferative potential in
order to expand robustly upon secondary infection, rapidly re-
express cytotoxic proteins and cytokines upon restimulation,
and sustain memory T cell homeostasis in the absence of infec-
tion by undergoing cytokine-dependent cell division (Kaech and
Wherry, 2007). A small population of CD8+ effector cytotoxic
lymphocytes (CTLs) cells survive the effector-to-memory transi-
tion and acquire these hallmark memory properties, whereas the
majority (80%–90%) of effector cells undergo a program of296 Immunity 31, 296–308, August 21, 2009 ª2009 Elsevier Inc.terminal differentiation in which they maintain effector functions
but losememory cell potential, longevity, and strong proliferative
responses (Fearon et al., 2001; Klebanoff et al., 2006; Lanzavec-
chia and Sallusto, 2002). A major goal in the field of memory
CD8+ T cell biology has been to understand the factors that
determine the balance between memory cell potential and
terminal differentiation.
During some infections, surface protein expression can be
used to distinguish the subpopulations of antigen-specific
effector andmemory cells that achieveamore terminally differen-
tiated state from those that aremore likely to acquire thememory
cell properties outlined above. For example, during lymphocytic
choreomeningitis virus (LCMV), Listeria, Toxoplasma gondii,
and murine cytomegalovirus virus infections, terminally differen-
tiated short-lived effector cells that express high amounts of the
NK cell maker KLRG1 (killer cell lectin-like receptor G1) and low
amounts of IL-7Ra (referred to as IL-7R) have a markedly shorter
lifespan and reduced proliferative capacity in response to the
homeostatic cytokines IL-7 and IL-15, or secondary antigenic
challenge compared to effector cells with a KLRG1loIL-7Rhi
phenotype (Huster et al., 2004; Joshi et al., 2007; Kaech et al.,
2003; Sarkar et al., 2008; Schluns et al., 2000; Snyder et al.,
2008; Voehringer et al., 2001; Wilson et al., 2008). In contrast,
the KLRG1loIL-7Rhi effector cells survive the effector-to-memory
transition better, have a longer lifespan, and acquire the ability to
proliferate well in response to both homeostatic cytokines and
antigenic rechallenge (Hikono et al., 2007; Joshi et al., 2007;
Sarkar et al., 2008). In addition, memory cells that express high
amounts of CD62L (referred to as central memory, Tcm), CD27,
and CXCR3, which also produce IL-2 and express low amounts
ofCD43 andcytotoxicmolecules, aremore ‘‘functionallymature’’
memory cells (i.e., cells with enhanced proliferative capacity
and longevity). These cells accumulate and dominate the
memory population with time in lymphoid tissues, whereas
end-stage cells with a CD62Llo (termed ‘‘effector memory,’’
Tem) KLRG1hiIL-7RloCD27loCXCR3loCD43hi phenotype typically
decay but are often better maintained in peripheral tissues such
as the liver and lung (Bachmann et al., 2005; Badovinac and
Harty, 2007; Hikono et al., 2007; Kaech et al., 2002; Wherry
et al., 2003). At the time of CD8+ T cell priming, decreasing the
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generates an activated cell population that acquires several
phenotypic and functional characteristics associated with a
more mature memory CD8+ T cell population (Badovinac et al.,
2004, 2005; Badovinac and Harty, 2007; Cannarile et al., 2006b;
Heffner and Fearon, 2007; Ichii et al., 2004; Intlekofer et al.,
2008; Joshi et al., 2007; Sarkar et al., 2007). Some key signals
involved in this process are the cytokines IFN-g and IL-12 and
the transcriptional regulators T-bet, Id2, Bmi-1, Bcl6, and Bcl6b
(Badovinac et al., 2004, 2005; Badovinac et al., 2004; Badovinac
and Harty, 2007; Cannarile et al., 2006b; Heffner and Fearon,
2007; Ichii et al., 2004; Intlekofer et al., 2008; Joshi et al., 2007;
PearceandShen,2007;Sarkaret al., 2007;Takemotoetal., 2006).
To better understand memory cell development and matura-
tion, we focused on B lymphocyte-induced maturation protein-
1 (Blimp-1; encoded by Prdm1), a transcriptional repressor that
is required for the terminal differentiation of B cells into plasma
cells, as well as the terminal differentiation of other diverse cell
types (Horsley et al., 2006; Magnusdottir et al., 2007; Martins
and Calame, 2008; Ohinata et al., 2005; Shapiro-Shelef et al.,
2003; Turner et al., 1994). Because it is a critical regulator of
terminal differentiation, we hypothesized that Blimp-1 might
positively regulate the formation of terminally differentiated
CD8+ T cell subsets and potentially negatively regulate the
process of memory cell maturation. Previously, Blimp-1 was
found to play an important role in T cell homeostasis (Kallies
et al., 2006; Martins et al., 2006). Blimp-1 deficiency in T cells
during development results in a lethal inflammatory disease
associated with excess accumulation of peripheral CD44hi
CD62Llo-activated CD4+ and CD8+ T cells, and greater numbers
of herpes simplex virus-specific memory CD8+ T cells form in
these mice (Kallies et al., 2006; Martins et al., 2006). However,
the precise role of Blimp-1 in the differentiation of antigen-
specific effector and memory CD8+ T cells could not be properly
assessed in these studies because of the added complications of
ongoing inflammatory disease and poor regulatory T cell function
in mice lacking Prdm1 expression in the entire T cell compart-
ment. Another study demonstrated that Blimp-1mRNA is prefer-
entially expressed in the short-lived effector cell subset of LCMV
antigen-specific CD8+ T cells, although no functional role for
Blimp-1 in CD8+ T cell differentiation has been described (In-
tlekofer et al., 2007). In this study, we define a critical role for
Blimp-1 in regulating thebalancebetween terminal differentiation
and memory cell development by showing that Blimp-1 not only
controls the terminal differentiation of antigen-specific CD8+
T cells, but also that it affects the rate at which they acquire hall-
mark memory cell properties.
RESULTS
Blimp-1 Expression in Subsets of Effector
and Memory CD8+ T Cells
Using ‘‘P14 chimeric’’ mice, which contain a small number
(5,000) of Thy1.1+ P14 CD8+ T cells that recognize the
DbGP33-41 epitope of LCMV, we previously compared the gene
expression profiles of naive and LCMV-specific effector and
memory CD8+ T cells using DNA microarrays (Wherry et al.,
2007). This analysis showed that Prdm1mRNA was upregulated
in day 8 effector CTLs compared to naive CD8+ T cells, but de-cayed as memory T cells formed between days 40–100 postin-
fection (p.i.). Using quantitative real-time PCR (qRT-PCR), we
observed a similar pattern of Prdm1 mRNA expression in
LCMV-specific P14 CD8+ T cells (Figure 1A). To investigate
Blimp-1 expression at the single-cell level, we infected BAC
transgenic (tg) reporter mice that express YFP under the control
of Prdm1 regulatory elements (Blimp-1-YFP) with LCMV.
Although less than 1% of CD44loCD62Lhi naive CD8+ T cells
expressed Blimp-1-YFP, Blimp-1 was upregulated in 80% of
LCMV-specific effector CD8+ T cells and then progressively
declined thereafter, both in terms of the percent of cells express-
ing Blimp-1-YFP as well as the amount expressed on a per-cell
basis (i.e., the median fluorescence intensity (MFI) of YFP) (Fig-
ure 1B). Together, these data showed that Blimp-1 mRNA was
induced in most effector CD8+ T cells during clonal expansion,
but its expression gradually declined during the effector-to-
memory transition because the memory T cell population func-
tionally matured.
Next, we explored whether Blimp-1 expression was differen-
tially regulated betweendifferent subsets of effector andmemory
CD8+ T cells during LCMV infection. In agreementwith previously
published data, Blimp-1 mRNA, protein, and YFP reporter
expression were increased 2- to 4-fold in terminally differenti-
ated KLRG1hiIL-7Rlo short-lived effector cells (termed SLECs),
compared to KLRG1loIL-7Rhi memory precursor effector cells
(MPECs) (Figures 1C–1F) (Intlekofer et al., 2007). Heightened
Blimp-1 expression continued to be maintained even in the
memory population in KLRG1hiIL-7RloCD27loCD62Llo (Tem) cells
(Figures 1C–1F). In contrast, the KLRG1loIL-7Rhi and
CD27hiCD62Lhi (Tcm) subsets became preferentially enriched
with Blimp-1-YFPlo cells between days 10–40 p.i. (Figure 1E,
note the red highlighting in quadrant 3, left panels, and quadrant
2, right panels). These data show that Blimp-1 expression is ex-
tinguished in the population because functionallymature subsets
of CD8+ Tcm cells that have increased longevity and proliferative
responses to both antigen and homeostatic cytokines form
(Hand et al., 2007; Hikono et al., 2007; Joshi et al., 2007; Wherry
et al., 2003).
Blimp-1 Deficiency Enhances the Survival
of Effector Cells
To investigate the functionofBlimp-1 ineffectorandmemoryCD8+
T cell development, we generated mice that were deficient in
Blimp-1 inCD8+Tcells bycrossingmicecontaininga loxP-flanked
Prdm1gene (Prdm1flox/flox) (Martins et al., 2006) to transgenicmice
expressing the Cre recombinase under the control of the human
Granzyme B promoter (GzB-cre) (Jacob and Baltimore, 1999).
For simplicity, we will refer to GzB-cre+; Prdm1flox/flox animals as
‘‘Prdm1/’’ and their littermate controls (GzB-cre+; Prdm1+/+ or
GzB-cre; Prdm1flox/flox) as ‘‘WT.’’ Unlike the mice in which
Blimp-1 is deleted during thymic development (Kallies et al.,
2006;Martinset al., 2006), in this systemBlimp-1 isexpressednor-
mally until CD8+ T cells are activated and uninfected Prdm1/
mice did not demonstrate abnormal T cell activation (data not
shown). Additionally, deletion efficiency reaches 85%–95% of
virus-specific CD8+ T cells during LCMV infection (Figure S1 avail-
able online) (Chappell et al., 2006; Maris et al., 2003).
Using these mice, we found that Blimp-1 deficiency markedly
increased effector cell survival after infection. Eight days afterImmunity 31, 296–308, August 21, 2009 ª2009 Elsevier Inc. 297
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Figure 1. Blimp-1 Is Preferentially Expressed in Terminally Differentiated LCMV-Specific Effector and Memory CD8+ T Cells
(A) Relative Prdm1 mRNA expression (±SEM) in naive or LCMV-specific P14 CD8+ T cells measured by qRT-PCR. n = 8 to 9 independent samples/time point.
(B) Naive (CD44loCD62Lhi) or DbGP33-41-specific CD8
+ T cells in the spleen of Blimp-1-YFP BAC tg mice were analyzed, and mean percentage (shown in black)
and MFI (shown in green) of Blimp-1-YFPhi cells is shown (±SEM; nR 6 mice/time point).
(C) Relative expression of Prdm1mRNA (±SEM) in KLRG1loIL-7Rhi and KLRG1hiIL-7Rlo P14 CD8+ T cells in the spleen from days 8, 15, and 60 p.i. as measured by
qRT-PCR.
(D) Blimp-1 (or Grp94) protein expression in KLRG1hiIL-7Rlo (SLEC) or KLRG1loIL-7Rhi (MPEC) P14 effector CD8+ T cells purified by flow cytometry at 8–10 days
p.i. Fold change represents average over 3 independent experiments (±SEM).
(E and F) Blimp-1-YFP expression was analyzed in P14 BAC tg CD8+ T cells stained with antibodies to IL-7R and KLRG1 or CD27 and CD62L in the (E) blood or (F)
spleen at days 10–40 p.i. nR 3 experiments each with 2 to 3 mice per time point. (E) Percentages of cells in each quadrant is shown. Histogram plots below each
contour plot show the percent of Blimp-1-YFPlo cells andMFI of YFP in each quadrant. (F) Line graph shows the percent (±SEM) of Blimp-1-YFPhi cells in KLRG1hi
or KLRG1lo DbGP33-41-specific CD8
+ T cells in the spleen.298 Immunity 31, 296–308, August 21, 2009 ª2009 Elsevier Inc.
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Figure 2. Blimp-1 Deficiency Increases Effector CD8+ T Cell Survival and Prevents Terminal Effector Cell Differentiation
(A) Representative plots of splenic DbGP33-41 and D
bNP396-404 tetramer
+ CD8+ T cells at 8 and 60 days after LCMV infection inWT and Prdm1/mice (percent of
tetramer+ cells CD8+ T cells ± SEM is indicated).
(B) Prdm1/ (white bars) or WT littermate controls (black bars) were infected with LCMV, and numbers of LCMV-specific CD8+ T cells in the spleen (±SEM) were
enumerated by IFN-g intracellular cytokine staining (ICCS) after 5 hr stimulation with NP396-404, GP33-41, and GP276-286 peptides. Note that numbers based on
tetramer staining are similar to those based on ICCS. n = four experiments each with 2 to 3 animals per group per time point.
(C, D, and E) Combined number (±SEM) of DbGP33-41-and D
bNP396-404 tetramer
+ CD8+ T cells in various tissues at days (C) 8, (D) 35, and (E) 150 p.i. in spleen
(SPL), inguinal lymph nodes (LN), bone marrow (BM), liver (LV), and lung (LG).
(F) Expression of IL-7R and KLRG1 (left plots) or CD62L and CD27 (right plots) in DbGP33-41 tetramer
+ CD8+ T cells at day 8 or day 60 p.i. Mean percentages
(±SEM) of 5–12 mice per time point.
(G) Percent (±SEM) of CD62Lhi DbGP33-41-specific CD8
+ T cells in the spleens of WT (black squares) or Prdm1/ (open squares) animals after LCMV infection.LCMV infection, similar frequencies of LCMV-specific CD8+
T cells were observed in the spleens of Prdm1/ and WT
mice (Figure 2A). The Prdm1/ mice also generated slightly,
but not significantly, increased numbers of LCMV-specific
effector CD8+ T cells in the spleen, similar numbers in several
other tissues, and significantly more effector cells in the lymph
nodes (LNs) and bone marrow (BM) as assessed by staining
for both MHC class I tetramers and intracellular IFN-g after
in vitro stimulation (Figures 2A–2C). Interestingly, the effector
CD8+ T cell death that normally follows viral clearance wassubstantially decreased in the Prdm1/ mice; initially 5-fold
more LCMV-specific memory CD8+ T cells persisted in the
spleen and other tissues (especially the LNs and BM) of the
Prdm1/ animals (Figures 2B and 2D). BrdU-labeling studies
during these time periods did not show more proliferation in
Prdm1/ cells compared to WT cells, indicating that the
Prdm1/ effector cells survived better than WT cells (data not
shown). After 5 months, the number of LCMV-specific Prdm1/
CD8+ T cells declined to that found inWTmice (except in BMand
LNs), indicating that the initial enhancement in survival wasImmunity 31, 296–308, August 21, 2009 ª2009 Elsevier Inc. 299
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mechanisms (Figures 2B and 2E).
Increased Memory Precursor Cell Formation
in Prdm1/ Effector CD8+ T Cells
Because Blimp-1 was preferentially expressed in more termi-
nally differentiated subsets of effector and memory CD8+
T cells, we hypothesized that it might play a role in the formation
of these cells. Indeed, Prdm1/ mice formed profoundly fewer
effector cells with a KLRG1hiIL-7Rlo (SLEC) phenotype, and there
was a corresponding increase in both the percentage and
number of KLRG1loIL-7Rhi (MPEC phenotype), CD27hi, and
CD62Lhi (Tcm) effector CD8+ T cells in the spleen, liver, and lungs
(Figure 2F and data not shown). Normally, the WT memory pop-
ulation gradually accumulates CD62Lhi Tcm cells, but Prdm1/
mice accumulated a larger percentage of Tcm cells (and
KLRG1loIL-7Rhi cells) at a faster rate than WT mice (Figures 2F
and 2G). Effector and memory CD8+ T cells from the Prdm1/
animals had higher expression of CD95 (Fas) as previously
described (Kallies et al., 2006), but similar expression of CD44,
CD43, bcl-2, andCD122 compared toWT cells (data not shown).
Thus, in the absence of Blimp-1, several phenotypic changes
that normally occur during the effector-to-memory transition
were accelerated, and a more mature-looking memory CD8+
T cell population with an increased number of Tcm cells devel-
oped at earlier time points after infection.
In the GzB-cre system, Prdm1 is deleted in a proportion of
granzyme B-expressing NK and virus-specific CD4+ T cells
(40% and 10%, respectively) (Maris et al., 2003). Therefore,
to specifically isolate the Blimp-1 deficiency to CD8+ T cells,
we examined two additional experimental systems. First,
Prdm1 was deleted in P14 CD8+ T cells using CD4-cre (CD4-
cre Prdm1/ = CD4-cre+; Prdm1flox/flox and WT littermate
controls = CD4-cre+; Prdm1+/+), and small numbers of these
cells were adoptively transferred into congenic B6 mice to
generate chimeric mice that were subsequently infected with
LCMV. The results from these experiments confirmed many of
the phenotypes observed in the GzB-cre system, indicating
that the aforementioned phenotypes were intrinsic to the
Blimp-1-deficient CD8+ T cells (Figure S2A). However, genetic
incompatibilities prevented long-term studies in these animals
due to deletion of donor P14 cells. Therefore, we generated an
additional experimental system involving mixed bone marrow
chimeras (BMC) whereby bone marrow from Ly5.1+ Cd8a/
animals was mixed in a 90:10 ratio with bone marrow from either
Ly5.2+ GzB-cre; Prdm1flox/flox (BMC WT) or Ly5.2+ GzB-cre+;
Prdm1flox/flox (BMC Prdm1/) and used to reconstitute lethally
irradiated Ly5.1+ recipient mice. Two months later, these mice
were infected with LCMV. The phenotypes of antigen-specific
effector and memory CD8+ T cells from these mice reconfirmed
those found in the above systems (Figure S3A; data not shown).
As in the GzB-cre system, the Prdm1/ effector cells from the
mixed BMC also showed reduced cell death between days 7
and 35 p.i. compared to WT cells (Figure S3B).
The Transcriptional Profile of Blimp-1-Deficient
Effector Cells Resembles that of MPECs
To better understand the mechanisms by which Blimp-1 regu-
lates the balance between terminal differentiation and mainte-300 Immunity 31, 296–308, August 21, 2009 ª2009 Elsevier Inc.nance of memory cell potential, we compared the gene expres-
sion profiles of WT and Prdm1/ LCMV-specific effector CD8+
T cells using Illumina BeadChips. Of the 24,000 genes
analyzed, 128 genes were significantly (p < 0.05) differentially
expressed, and of these, 70% (87 genes) showed increased
mRNA in the Prdm1/ effector CD8+ T cells compared to the
WT cells (Table 1 and Table S1), in agreement with Blimp-1 being
a transcriptional repressor (Huang, 1994). To further analyze the
gene expression profile of the Prdm1/ effector cells, we cate-
gorized several of the differentially expressed genes into distinct
functional groups (Table 1). Some potential Prdm1 gene targets,
such as Bcl6, Tcf7, Tbx21 (encodes T-bet), and Kit, were then
confirmed using qRT-PCR or flow cytometry (Figure 3). A
number of the differentially expressed genes contain predicted
Blimp-1 binding sites (BS): some are regulated by Blimp-1 in
other cell types (Id2, Xcl1, and Cd83), and others are known
direct targets of Blimp-1 (Bcl6, Id3, and Prdm1 itself) (Table 1,
Column E) (G.M., K.C. and M. Cimmino unpublished data,
Martins and Calame, 2008 and Gong and Malek, 2007). These
data suggest that control of terminal differentiation by Blimp-1
may share common features across different cell types.
Lastly, we compared the Prdm1/ effector cell gene signa-
ture to that of MPECs, as previously described by our lab using
Affymetrix GeneChips (Joshi et al., 2007) (Table 1, compare
columns A and D). Although the magnitude of the differential
expression cannot be directly compared across the two different
microarray platforms, similarity in terms of the relative increase
or decrease in gene expression can be assessed. Of the 128
genes differentially expressed in Prdm1/ effector cells,
90% showed the same trend in expression in MPECs
compared to SLECs (Table 1 and data not shown). Thus, it
appears that Blimp-1 represses many of the genes that control
memory CD8+ T cell potential and the development of memory
CD8+ T cell properties.
Blimp-1-Deficient CTLs Have Altered Effector Molecule
Expression
Because the mRNA transcripts of certain effector molecules
were downregulated in Prdm1/ versus WT cells, we next
sought to establish whether Blimp-1 deficiency might perturb
CTL function during viral infection. First, we examined the ability
of effector and memory WT and Prdm1/ CD8+ T cells to
produce IFN-g, TNFa, and IL-2 after 5 hr in vitro stimulation
with peptide (Figure 4A). The numbers of IFN-g-producing
CD8+ T cells corresponded closely to those obtained with
MHC class I tetramer staining between the two groups (compare
Figures 2A and 4A), indicating no differences in the frequency of
IFN-g+ virus-specific CD8+ T cells. In addition, similar frequen-
cies of TNFa-producing CD8+ T cells were observed between
the two groups (data not shown). However, a considerably larger
percentage of Prdm1/ effector CD8+ T cells produced IL-2
compared to WT cells (Figure 4A), which translated into an over-
all increase in the percentage of polyfunctional, triple cytokine-
producing (IFN-g, TNFa, and IL-2) cells in the Prdm1/ animals.
Notably, though, the overall amount of IFN-g produced on a per-
cell basis (MFI) was reduced in effector and memory Prdm1/
CD8+ T cells (Figure 4A).
When the expression of granzyme B (GzB) protein was exam-
ined, we found that 50%–60% of the Prdm1/ effector CD8+
Immunity
Blimp-1 and Memory CD8+ T Cell DifferentiationTable 1. Select Genes Significantly Differentially Expressed between WT and Prdm1/ Effector CD8+ T Cells
A B C D E
Fold Change
Prdm1//WTa
Gene
Symbol Gene Name
Fold Change
IL-7Rhi/IL-7Rlo b
Predicted
Blimp-1 BSc
Effector Molecules
2.3 Gzmm granzyme M (lymphocyte met-ase 1) 1.6 3
6.2 Gzma granzyme A 1.7 1
2.8 FasL Fas ligand (tumor necrosis factor ligand superfamily, 6) 1.1 1
2.8 Prf1 perforin 1 2.1 0
Cytokine and Chemokine Receptors
13.4 Ccr7 chemokine (C-C motif) receptor 7 35.7 2
5.7 Ccr6 chemokine (C-C motif) receptor 6 8.3 3
2.8 Il7r interleukin 7 receptor (CD127) 36.4 2
2.4 Sell selectin, lymphocyte (CD62L) 11.3 4
7.8 Edg8 endothelial differentiation, sphingolipid G-protein-coupled receptor 8 20.5 0
6.5 Cx3cr1 chemokine (C-X3-C) receptor 1 5.6 0
3.5 Sema4a semaphorin 4A 1.2 0
3.5 Cxcr6 chemokine (C-X-C motif) receptor 6 1.6 0
Cytokines, Chemokines, and Secreted Factors
8.5 Xcl1 chemokine (C motif) ligand 1 1.6 0
4.4 Cxcl10 chemokine (C-X-C motif) ligand 10 3.8 2
2.8 F2rl1 coagulation factor II (thrombin) receptor-like 1 5.7 2
2.4 Mif macrophage migration inhibitory factor (Mif) 1.4 0
Costimulatory and Inhibitory Receptors
3.2 OX-40 tumor necrosis factor receptor subfamily, member 4 1.5 0
2.3 Ctla4 cytotoxic T-lymphocyte-associated protein 4 3.1 1
2.0 Tnfrsf25 tumor necrosis factor receptor superfamily 25 3.4 0
2.0 Cd83 CD83 antigen 3.7 0
4.3 Klrg1 killer cell lectin-like receptor subfamily G 1 11.4 3
Transcription Factors
9.2 Prdm1 PR domain containing 1 (Blimp-1), EXON 4 (not floxed) N/A 1
6.9 Id3 inhibitor of DNA binding 3 11.3 4
6.4 Tcf7 transcription factor 7, T cell specific 11.1 0
2.4 Pou6f1 POU domain, class 6, transcription factor 1 5.8 0
2.1 Bcl6 B cell leukemia/lymphoma 6 2.6 0
3.8 Zfhx1b zinc finger homeobox 1b 9.3 1
2.4 Prdm1 PR domain containing 1 (Blimp-1), EXON 8 (floxed) 2.1 1
2.2 Id2 inhibitor of DNA binding 2 1.2 0
2.2 Tbx21 T-box 21 (Tbet) 1.5 1
Cell Signaling (Including Cell-Cycle and Survival Factors)
3.1 Kit kit oncogene 4.1 0
2.9 Cables1 Cdk5 and Abl enzyme substrate 1 3.5 1
2.9 Lrig1 leucine-rich repeats and Ig-like domains 1 3.9 2
2.8 Spi2a serine proteinase inhibitor, clade A, member 3G (Serpina3g) 3.7 1
2.5 Ccnd3 cyclin D3 1.3 0
2.5 Anxa1 annexin A1 2.8 1
2.2 Socs2 suppressor of cytokine signaling 2 2.3 0
aData represent theaverageof four independent samplesof LCMV-specificWTandPrdm1/effectorCD8+Tcells sortedatday8p.i. by flowcytometry
and analyzed using Illumina SentrixMouseRef-8 Expression BeadChips. Positive fold change values aremore highly expressed inPrdm1/ cells (bold
lettering); negative fold change values are more highly expressed in WT cells (full list in Table S1). All fold changes are statistically significant, p < 0.05.
bData from 3 independent samples of LCMV-specific P14 IL-7Rhi and IL-7Rlo effector CD8+ T cells sorted at day 7 p.i. by flow cytometry and analyzed
using Affymetrix U430v2 genechips (Joshi et al., 2007).
c Blimp-1 binding site (BS) predictions are based on algorithms from Genomatix software.Immunity 31, 296–308, August 21, 2009 ª2009 Elsevier Inc. 301
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Figure 3. Blimp-1 Deficiency Alters the Expression of Genes Known
to Regulate Effector and Memory CD8+ T Cell Differentiation
(A–C) qRT-PCR analysis of Bcl6 (A), Tbx21 (B), and Tcf7 (C) mRNA expression
in WT and Prdm1/ effector CD8+ T cells from day 8 p.i. or WT naive cells
(CD44loCD62Lhi), SLEC (KLRG1hiIL-7Rlo), or MPEC (KLRG1loIL-7Rhi) from
day 8 p.i., and memory CD8+ T cells from day 150 p.i. Fold change relative
to naive cells (±SEM) are representative of two to three independent experi-
ments each with 2 to 3 samples. *p < 0.05.
(D) Percent (±SEM) Kit receptor positive DbGP33-41-tetramer
+ CD8+ T cells
from WT (gray histogram) and Prdm1/ (black line) animals 8 days after
LCMV infection.302 Immunity 31, 296–308, August 21, 2009 ª2009 Elsevier Inc.T cells initially (day 5 p.i.) expressed GzB (compared to 90% in
WT effector cells), but this rapidly decayed to near undetectable
levels by day 7 p.i. (Figure 4B). Despite this profound reduction in
GzB expression, cytotoxic activity of Prdm1/CD8+ T cells was
only marginally affected based on in vivo cytotoxicity assays,
indicating that other cytotoxic pathways were unaffected by
Blimp-1 deficiency (data not shown). The decreased GzB and
increased IL-2 expression was also recapitulated in the P14
CD4-cre and BMC Prdm1/ systems (Figures S2B and S3A),
although the depressed IFN-g staining was not found in the
P14 CD4-cre system, perhaps due to differences in the poly-
clonal TCR repertoire versus that of the high affinity P14 TCR
(data not shown). Despite the modest effects on CTL function
in the GzB-cre Prdm1/ animals, the clearance of LCMV by pla-
que assay technique was slightly delayed by 1 to 2 days in the
majority of Prdm1/ animals (Figure 4C and data not shown;
note that virus was not detected in the spleen, liver, or kidney
of Prdm1/ mice at day 15 p.i.). Nonetheless, the Prdm1/
memory CD8+ T cells were capable of providing a protective
immune response because LCMV-immune Prdm1/ mice
cleared a 2 infection with a more virulent strain of LCMV (cl.
13) that normally causes chronic infection and cannot be cleared
in the absence of functional memory CD8+ T cells (as measured
by serum viral titers at day 5 p.i., data not shown). Interestingly,
restimulation of Prdm1/ memory CD8+ T cells did not
‘‘reverse’’ their phenotypes because the 2 Prdm1/ effector
CD8+ T cells maintained a IL-7RhiCD27hiCD62LhiKLRG1loGzBlo
phenotype compared to WT cells (Figure 4D). This indicated
that, even with repeated stimulation, CD8+ T cells cannot bypass
the need for Blimp-1 for terminal differentiation.
Blimp-1 Regulates the Proliferative Responses
of Virus-Specific CD8+ T Cells
The ability to proliferate robustly in response to secondary infec-
tion and homeostatic cytokines is a hallmark property of memory
cells (Bachmann et al., 2005; Badovinac andHarty, 2007; Hikono
et al., 2007; Kaech et al., 2002; Wherry et al., 2003). Because
Blimp-1 was preferentially expressed in memory T cell subsets
that have relatively reduced proliferative responses, we first
confirmed that Blimp-1 itself marked cells with reduced prolifer-
ative capacity by transferring equal numbers of sorted Blimp-1-
YFP+ and Blimp-1-YFP P14 memory T cells from the same
chimeric mice into naive congenic recipient mice that were
subsequently infected with recombinant Listeria-expressing
GP33-41 (rLM33) and analyzing their numbers 7 days later
(Figure 5A). As predicted, the Blimp-1-YFP+ cells expanded
less than the Blimp-1-YFP population, indicating that Blimp-1
expression directly corresponds to memory T cells with
decreased proliferative capacity.
Next, we tested whether the absence of Blimp-1 also
impacted the proliferative responsiveness of effector cells to
antigen in vitro and in vivo. To do this, we first examined cell divi-
sion by CFSE-dilution in purified effector cells from WT and
Prdm1/ animals incubated in vitro with peptide for 48 hr. In
these experiments, Prdm1/ CD8+ T cells underwent more
extensive cell division than WT cells with less than 15% of WT
effector cells dividing compared to >50% of Prdm1/ effector
cells (Figure 5B). To test if similar results were found in vivo, equal
numbers of day 8 LCMV P14 WT or CD4-cre Prdm1/ effector
Immunity
Blimp-1 and Memory CD8+ T Cell Differentiationcells sorted from ‘‘chimeric’’ mice were transferred into new
naive congenic recipients that were then infected with recombi-
nant vaccinia virus expressing GP33-41 (rVV33). On a per-cell
basis, the secondary expansion of Blimp-1-deficient effector
cells was4-fold greater than that of theWT effector CD8+ cells,
indicating that Blimp-1 can suppress the ability of effector CD8+
T cells to proliferate when restimulated with antigen (Figure 5C).
However, when we performed similar experiments with the WT
and Prdm1/ memory CD8+ T cells found 90 days p.i., their
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Figure 4. Blimp-1 Deficiency Alters CTL
Differentiation
(A) Prdm1/ or WT littermate controls were in-
fected with LCMV and analyzed for IFN-g and
IL-2 production at days 8 and 60 p.i. Representa-
tive plots showing frequency of GP33/34-41-specific
and NP396-404-specific CD8
+ T cells producing
IFN-g and IL-2 based on ICCS after 5 hr stimulation
with peptide (note that GP33-41 peptide activates
both DbGP33-41- and K
bGP34-41-specific CD8
+
T cells; similar results observed for GP276-286-
specific CD8+ T cells). Mean (±SEM) IFN-g MFI is
indicated next to plots. Bar graphs to right show
the percent of IFN-g+ cells that coproduce IL-2.
Note that no difference in TNFa was noted
between the two groups of animals. *p < 0.05.
(B) Granzyme B protein expression (percent
GzB+ ± SEM) of WT (gray histogram) and
Prdm1/ (black line) DbGP33-41-specific effector
CD8+ T cells in the spleen 5 and 7 days after LCMV
infection.
(C) Serum LCMV viral titers in WT (black boxes)
and Prdm1/ (white boxes) animals at various
points after infection. n = 5–8 mice per group per
time point. LOD, limit of detection.
(D) Phenotype of 2 effector CD8+ T cells from
LCMV immune WT (shaded) and Prdm1/ (black
line) mice reinfected with LCMV-cl. 13 7 days prior.
Virus was cleared in the serum in both groups by
day 5 p.i.
recall responses were not significantly
different (Figure 5D). This result was not
entirely unexpected since, by this time,
WT and Prdm1/ memory CD8+ T cells
had more similar phenotypes (Figures
2F, 2G, and 4A). These results suggest
that Blimp-1 acts to limit the proliferative
potential of effector CD8+ T cells as they
terminally differentiate, but as Blimp-1
expression naturally decays over time,
the WT memory CD8+ T cells ‘‘catch up’’
to and attain similar proliferative
responses to antigenic challenge as
Prdm1/ cells.
To determine if Blimp-1 also regulated
effector CD8+ T cell proliferative re-
sponses to homeostatic cytokines, WT
and Prdm1/ LCMV-specific effector
CD8+ T cells were CFSE-labeled and
transferred into g-irradiated mice, and
donor cells were examined 6 days later
in the spleen. In a third group of mice, WT memory CD8+
T cells (from day 90 p.i.) were transferred for comparison.
Similar to WT memory cells, Prdm1/ effector CD8+ T cells
proliferatedmore extensively than their WT effector counterparts
(Figure 5E), even when the IL-7Rhi populations were compared
directly (data not shown). In addition, larger numbers of donor
CD8+ T cells were recovered from animals that received
Prdm1/ versus WT effector cells (data not shown). Together,
these data indicate that Blimp-1 antagonizes effector CD8+Immunity 31, 296–308, August 21, 2009 ª2009 Elsevier Inc. 303
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B Figure 5. Blimp-1 Expression Correlates
with Cells of Lower Proliferative Capacity
(A) Blimp-1-YFP+ (black bar) or Blimp-1-YFP
(white bar) Thy1.1+ P14 memory CD8+ T cells
from day 60 p.i. chimeric mice were sorted by
flow cytometry, and 25,000 cells were transferred
into naive Thy1.2+ B6 recipients that were subse-
quently infected with rLM33. The number (±SEM)
of donor cells recovered from the spleen 7 days
p.i. was calculated. *p < 0.05.
(B) GzB-cre Prdm1/ (black line) or WT littermate
(shaded) effector CD8+ T cells from days 8–10 p.i.
were CFSE-labeled, stimulated with GP33-41
peptide, and analyzed for cell division 48 hr later.
Data representative of four independent experi-
ments each with 2 to 3 samples.
(C) Day 7 CD4-cre Prdm1/ (white bar) or WT
littermate (black bar) P14 effector cells were puri-
fied from ‘‘chimeric’’ mice using FACS, and
25,000 cells were transferred into naive congenic
recipients that were subsequently infected with
rVV33. The number of secondary effector cells in
the spleen (±SEM) was calculated 7 days post-
rVV33 infection. *p < 0.05.
(D) 50,000 DbGP33-41-specific CD8
+ T cells from
GzB-cre Prdm1/ (white bar) or WT (black bar)
mice infected 90 days previously with LCMV
were transferred into naive Rag-1/ recipients
that were subsequently infected with rLM33. The
number of secondary effector cells in the spleen
(±SEM) was calculated 7 days post-rLM33 infec-
tion. NSD, no significant difference.
(E) Purified GzB-cre Prdm1/ or WT effector
CD8+ T cells from day 10 p.i. or WT memory cells
from day 90 p.i. were CFSE labeled, transferred into g-irradiated recipients, and analyzed for cell division 6 days later. Histograms were gated on DbGP33-41-
specific CD8+ T cells. Similar results were found for NP396-404-specific cells. Cell division numbers and PI, proliferation index (mean number of cell divisions),
are indicated. Data are representative of three independent experiments each with 2 to 3 samples.T cell proliferative potential in response to antigenic and cytokine
stimulation, and that the decline of Blimp-1 expression in the
effector to memory transition directly contributes to the progres-
sive increase of Tcm cells that acquire enhanced proliferative
capacity and the ability to self-renew.
DISCUSSION
Formation and long-term survival of a functional memory CD8+
T cell population is critical for protective immunity, and this pop-
ulation is maintained for extended periods of time by long-lived,
nonsenescent, self-renewing cells (Fearon et al., 2001; Kaech
and Wherry, 2007; Lanzavecchia and Sallusto, 2002). How are
T cells with these properties generated during an immune
response? We propose that a small population of effector cells
evades terminal differentiation during clonal expansion and
acquires memory cell developmental potential. In this study,
we asked whether Blimp-1, a transcriptional repressor known
to regulate the terminal differentiation of diverse cell types, plays
a functional role in regulating effector and memory CD8+ T cell-
fate decisions (Horsley et al., 2006; Magnusdottir et al., 2007;
Ohinata et al., 2005; Shapiro-Shelef et al., 2003). Data from our
laboratory and others indicated that Blimp-1 is preferentially ex-
pressed in more terminally differentiated effector populations
and Tem cells (Intlekofer et al., 2007), and our studies here304 Immunity 31, 296–308, August 21, 2009 ª2009 Elsevier Inc.demonstrate that effector CD8+ T cells lacking Blimp-1 expres-
sion did not maintain normal expression of several cytolytic
molecules and developed almost entirely into memory cell
precursors that more rapidly acquired a Tcm cell phenotype
and mature memory features such as enhanced survival, higher
proliferative capacity, and increased IL-2 production. Thus,
Blimp-1 suppresses the formation of bothMPECs and Tcm cells,
and hence, its activity balances whether an activated CD8+ T cell
will terminally differentiate and acquire maximal CTL function or
whether it will maintain memory cell potential.
In general, after many acute infections such as LCMV, Listeria,
or Sendai virus, the memory CD8+ T cell population evolves over
time and slowly accumulates IL-7RhiKLRG1loCD62LhiCD27hi
Tcm cells that display the functionally mature characteristics of
enhanced survival and proliferation to antigen and homeostatic
cytokines and increased IL-2 production compared to Tem cells
(Bachmann et al., 2005; Hikono et al., 2007; Joshi et al., 2007;
Pearce and Shen, 2007; Tripp et al., 1995; Wherry et al., 2003).
In addition to demonstrating that this phenotypic and functional
maturation of the memory population correlates with a loss of
Blimp-1 expression, our studies suggest that Blimp-1 itself
negatively regulates the acquisition of these mature memory
features by effector cells. As suggested by our microarray
data, which showed a high degree of similarity in global gene
expression patterns between Blimp-1-deficient effector cells
Immunity
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genes probably account for the regulation of memory cell prop-
erties by Blimp-1. In terms of effector CD8+ T cell survival,
reduced cytotoxic molecule expression or increased expression
of some protease inhibitors (such as Spi-6 and Spi2a) that block
granzyme or cathepsin B activity have been proposed to
enhance CTL survival (Ashton-Rickardt, 2005; Badovinac et al.,
2000; Zhang et al., 2006, 2007). Indeed, Prdm1/ CTLs ex-
pressed lower amounts of granzyme B, granzyme A, fasL, and
perforin, and increased amounts of Spi2a. In addition, Prdm1/
effector cell survival may also be enhanced by higher OX-40
expression because OX-40 signaling can augment memory
T cell formation and its expression can be induced by IL-7 (Gas-
pal et al., 2005; Ruby et al., 2007). Finally, higher expression of
lymph node homing receptors CD62L and CCR7 and retention
in lymphoid organs may also contribute to the increased survival
of the Prdm1/ cells by increasing their exposure to prosurvival
cytokines at these sites (Link et al., 2007).
Another critical memory feature that we found to be regulated
by Blimp-1 is proliferative capacity. Populations of memory cells
that naturally express high amounts of Blimp-1 have poorer
proliferative responses to secondary recall challenge compared
to populations with low Blimp-1 expression, and effector cells
that genetically lack Blimp-1 expression proliferate more
robustly to both antigen and homeostatic cytokines compared
to their WT counterparts. In other cell types, Blimp-1 represses
proliferative responses via direct transcriptional inhibition of
the cell-cycle regulator myc (Horsley et al., 2006; Lin et al.,
1997). Although our microarray studies did not show a marked
difference inMycmRNA expression between WT and Prdm1/
effector CD8+ T cells, past analyses demonstrate an inverse rela-
tionship between Myc and Prdm1 expression in effector and
memory cells, suggesting the possibility that these factors may
interact in CD8+ T cells (Wherry et al., 2007). A final feature of
memory cells commonly observed is the ability to coproduce
multiple cytokines (referred to as ‘‘polyfunctionality’’), and we
found that a greater percentage of Prdm1/ effector and
memory T cells were polyfunctional and coproduced IFN-g,
TNFa, and IL-2 (albeit, average IFN-g expression was reduced
in the GzB-cre Prdm1/ cells compared to WT cells, but no
difference was observed in the CD4-cre P14 Prdm1/ cells).
The increased IL-2 production is consistent with reports that
Blimp-1 negatively regulates IL-2 expression in activated CD4+
and CD8+ T cells in vitro (Gong and Malek, 2007; Martins et al.,
2008) and that the Il2 locus is a direct target of Blimp-1 repres-
sion in CD4+ T cells (Martins et al., 2008).
One potential mechanism for the enhanced MPEC or Tcm
phenotype seen in the Prdm1/ effector cells could be that
Blimp-1 normally represses other transcriptional regulators that
promote memory cell development (and suppress terminal
differentiation), and therefore, in the absence of Blimp-1, these
factors are expressed at higher amounts. One such transcription
factor (TF), a candidate from ourmicroarray data and studies in B
cells, is the proto-oncogene Bcl6, which is a direct target of
Blimp-1 in both B and CD4+ T cells (Shaffer et al., 2002; Cimmino
et al., 2008). In germinal center B cells, Bcl6 and Blimp-1 mutu-
ally represses each other: Bcl6 inhibits Blimp-1 expression and
promotes the formation of long-lived memory B cells (Martins
and Calame, 2008; Shaffer et al., 2000; Toyama et al., 2002),whereas Blimp-1 inhibits Bcl6 expression and promotes the
formation of short-lived and long-lived antibody-secreting
plasma cells (Shaffer et al., 2002; Shapiro-Shelef et al., 2003).
In CD4+ T cells, Blimp-1 and Bcl-6 also mutually repress one
another with Bcl-6-enhancing Th1 cell differentiation and
Blimp-1-promoting Th2 cell differentiation (Cimmino et al.,
2008). In CD8+ T cells, increased Bcl6 expression can augment
both memory cell proliferative capacity as well as acquisition
of a Tcm phenotype (Ichii et al., 2002, 2004). Mice deficient in
Bcl6b, a close homolog of Bcl6, also demonstrate impaired
secondary recall responses (Manders et al., 2005). Our gene
expression studies found that Bcl6 is 2- to 3-fold increased
IL-7Rhi MPECs versus IL-7Rlo SLECs. Moreover, Bach2, another
repressor of Blimp-1 in B cells (Ochiai et al., 2006), is similarly up-
regulated 2- to 4-fold in IL-7Rhi MPECs (Joshi et al., 2007).
Although it is not clear from these studies whether it is the
amount of Bcl6 or Bcl6b or the amount of Blimp-1 expression
that is directly responsible for the phenotypes observed, taken
together, these data clearly indicate that the Blimp-1-Bcl6 axis
plays an important role in memory CD8+ T cell maturation.
The results from our microarray study also lend insight into
how Blimp-1 may interact with other transcriptional regulators
that are known to promote terminal differentiation. In particular,
the mRNAs of the TFs T-bet (Tbx21) and inhibitor of DNA binding
2 (Id2) were reduced in Prdm1/ effector cells compared to WT
cells. Similar to CD8+ T cells lacking Blimp-1, those lacking T-bet
and Id2 form an increased frequency of IL-7Rhi and CD62Lhi cells
(Cannarile et al., 2006a; Intlekofer et al., 2007; Joshi et al., 2007).
Blimp-1 and T-bet appear to positively regulate each others’
expression in effector CD8+ T cells because CD8+ T cells lacking
T-bet also produce less Prdm1 mRNA (data not shown;
Intlekofer et al., 2005), although a different relationship may
operate in activated CD4+ T cells because T-bet expression is
actually elevated in the absence of Blimp-1 (Cimmino et al.,
2008). A recent study has also found that XBP-1, a critical regu-
lator of plasma cell formation that is downstream of Blimp-1
activity in B cells, enhances the formation of terminally differen-
tiated KLRG1hi effector CD8+ T cells (Kamimura and Bevan,
2008).
Our study provides a deeper understanding of the transcrip-
tional network that governs effector cell fate decisions, and
further exploration of the downstream targets and upstream
regulators of Blimp-1 will help to better define this genetic
pathway. Indeed, little is known about the upstream signals
that regulate Blimp-1 expression in T cells. In B cells, IL-2,
IL-5, IL-6, IL-10, and IL-21 can induce Blimp-1 expression, and
STAT3 and STAT5, two transcription factors downstream of
some of these cytokines, also regulate Blimp-1 and Bcl6 expres-
sion (Calame, 2008). In T cells, IL-2, IL-4, and IL-12 have been
shown to induce Blimp-1 expression under certain in vitro condi-
tions, but it is not yet known how this treatment relates to CD8+
T cell differentiation in vivo during immune responses (Gong and
Malek, 2007). Thus, more work is needed to identify the signals
that modulate Blimp-1 expression in vivo in both T and B cells.
Improved understanding of Blimp-1 regulation could lead to
new types of vaccines and treatments that modulate Blimp-1
activity tominimize certain aspects of Blimp-1-mediated effector
CD8+ T cell terminal differentiation yet maximize other aspects of
memory CD8+ T cell differentiation.Immunity 31, 296–308, August 21, 2009 ª2009 Elsevier Inc. 305
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Mice, Infections, and Plaque Assays
C57BL/6 (B6) mice were obtained from the NCI (Frederick, MD). Thy1.1+ P14
TCR transgenic (tg) mice and generation of ‘‘P14 chimeric mice’’ via transfer
of 50,000 naive P14 CD8+ T cells (5,000 cells engraft) into B6 mice have
been described previously (Joshi et al., 2007). Rag1/ animals were from
the Jackson Laboratories (Bar Harbor, ME). Blimp-1-YFP BAC tg mice were
either directly infected or crossed to the P14 strain to create Blimp-1-YFP
P14 chimeric mice (see Supplemental Experimental Procedures for construct
details). Prdm1flox mice were crossed to CD4-cre mice (Cimmino et al., 2008;
Martins et al., 2006) or Granzyme B-cre mice (Jacob and Baltimore, 1999).
Mice were infected with 2 3 105 pfu LCMV-Armstrong (i.p.), 2 3 106 pfu of
LCMV clone 13 (i.v.), 23 104 cfu recombinant L. monocytogenes (i.v.) express-
ing the LCMV epitope GP33-41 (rLM33, a gift from Dr. H. Shen) (Kaech et al.,
2003), or 2 3 104 pfu vaccinia virus expressing GP33-41 (i.p.; rVV33), kindly
provided by Dr. R. Ahmed. Viral titers were measured by plaque assay (Wherry
et al., 2003). All animal experiments were done with approved Institutional
Animal Care and Use Committee protocols.
Cell Isolations, Surface, and Intracellular Staining and Antibodies
Lymphocytes were isolated as previously described (Joshi et al., 2007) or
sorted using a FACSAria. For CFSE labeling and all other above methods,
see Supplemental Experimental Procedures.
Gene Expression Profiling, qRT-PCR, and Immunoblotting
DNAmicroarray analysis was performed on four independent samples of day 8
WT or GzB-cre Prdm1/ effector cells FACS-purified based on CD8+ and
MHC Class I tetramers DbGP33-41 and D
bNP396-402 binding. RNA was isolated
using TRIzol (Invitrogen, Carlsbad, CA), followed by RNeasy mini elute Kit
(QIAGEN, Valencia, CA). For hybridization and analysis information as well
as qRT-PCR protocols, see Supplemental Experimental Procedures. Protein
lysates from 1 3 106 sorted day 9 p.i. KLRG1hiIL-7Rlo or KLRG1loIL-7Rhi
effector CD8+ T cells were processed and resolved by SDS-PAGE as
described previously (Hand et al., 2007). Blimp-1 was detected by immuno-
blotting using rat anti-Blimp-1 antibody at 1:200 (clone 6D3, Santa Cruz
Biotechnology Inc., Santa Cruz, CA), and expression was normalized to
expression of Grp94 (Hand et al., 2007).
Statistical Analysis
Standard two-tailed t tests assuming normal variance were used for all statis-
tical calculations. All error bars and variances represent standard error of the
mean, and asterisks on all graphs represent p < 0.05.
ACCESSION NUMBERS
Microarray data have been deposited into the GEO, accession number
GSE17211.
SUPPLEMENTAL DATA
Supplemental Data include three figures, one table, and Supplemental Exper-
imental Procedures and can be foundwith this article online at http://www.cell.
com/immunity/supplemental/S1074-7613(09)00323-9.
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